Eyconis will develop, manufacture and commercialize Ascendis’ TransCon ophthalmology assets, according to a Jan. 29 press release.
Eyconis now holds the exclusive rights to develop and commercialize TransCon ophthalmology products globally.
Ascendis will be eligible to receive development, regulatory and sales milestone payments of up to $248 million, plus-single digit royalties on global net sales of commercialized products, if any.
Eyconis will initially be based in Redwood City, Calif., and certain employees of Ascendis are expected to join the newly formed company, according to a Jan. 29 press release.
Eyconis will be led by Emmett Cunningham, MD, PhD, a senior partner at HealthQuest Capital. Oliver Boris Stauch will join Eyconis as COO after serving previously as head of ophthalmology at Ascendis Pharma.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
